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Abstract   
A DNA vaccine, SCIB1, incorporating two CD8 and two CD4 epitopes from TRP-2/gp100 
was evaluated in patients with metastatic melanoma. Each patient received SCIB1 via 
intramuscular injection with electroporation. The trial was designed to find the safest dose of 
SCIB1 which induced immune/clinical responses in patients with or without tumour. Fifteen 
patients with tumor received SCIB1 doses of 0.4-8 mg whilst 20 fully-resected patients 
received 2-8 mg doses. Twelve patients elected to continue immunization every 3 months for 
up to 39 months.   SCIB1 induced dose-dependent T cell responses in 88% of patients with 
no serious adverse effects or dose limiting toxicities. The intensity of the T cell responses 
was significantly higher in patients receiving 4 mg doses without tumor when compared to 
those with tumor (p< 0.01). In contrast, patients with tumor showed a significantly higher 
response to the 8mg dose than the 4 mg dose (p< 0.03) but there was no significant difference 
in the patients without tumor. One of 15 patients with measurable disease showed an 
objective tumor response and 7/15 showed stable disease. 5/20 fully-resected patients have 
experienced disease recurrence but all remained alive at the cut-off date with a median 
observation time of 37 months. A positive clinical outcome was associated with MHC-I and 
MHC-II expression on tumors prior to therapy (p=0.027). 
We conclude that SCIB1 is well tolerated and stimulates potent T cell responses in melanoma 
patients. It deserves further evaluation as a single agent adjuvant therapy or in combination 
with checkpoint inhibitors in advanced disease. 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
 
 
 4 
Introduction 
Checkpoint blockade has demonstrated anti-tumor responses in approximately 10-55% of 
melanoma patients 
1-4
. However, many patients do not respond 
5, 6
 and may benefit from an 
effective vaccine that stimulates high avidity T cell responses either as a single agent or in 
combination with checkpoint blockade.  
TRP-2 and gp100 are both crucial to melanin production and are therefore expressed by all 
pigment producing melanomas. Cloning of T cells from patients, showing spontaneous 
rejection of their melanomas, identified their targets as TRP-2180-188 and gp100174-190 and 
indicated that they were CD8 rejection epitopes 
7, 8
. This demonstrated that, at least in these 
patients, there was a T cell repertoire recognizing self-antigens with sufficient avidity to kill 
tumour cells. The question remains as to whether an effective vaccine could stimulate these T 
cells in a wider cohort of patients. 
We have previously shown in preclinical models that a DNA plasmid encoding T cell 
epitopes within the complementarity-determining regions of a human IgG1 antibody 
(ImmunoBody®) 
9
 and injected with electroporation (EP) stimulates high avidity T cell 
responses 
10
. T cell avidity is critically important in both viral infection and tumor models as 
only high avidity T cells mediate viral clearance and tumor eradication 
11-16
. EP increases 
DNA uptake over 1000-fold in comparison to injection alone and has an adjuvant effect 
resulting from local tissue damage and stimulation of pro-inflammatory cytokines 
17, 18
. 
ImmunoBody® acts by direct uptake of the DNA into antigen presenting cells which is 
transcribed, translated, processed and epitopes presented on the cell surface in combination 
with MHC. ImmunoBody®  can also be taken up by both antigen presenting cells and non -
antigen presenting cells and secreted. The secreted antibody is internalized via the high 
affinity FcγR1 receptor (CD64), on antigen presenting cells processed and cross presented on 
MHC-1. It is this combination of direct and cross presentation that elicits T cells with 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
 
 
 5 
sufficiently high avidity to eradicate established tumors in preclinical models 
9
. Furthermore, 
the frequency and avidity of T cell responses induced by ImmunoBody® are superior to those 
induced by immunization with DNA encoding full-length antigen, using naked peptides or 
peptides loaded onto dendritic cells 
10, 19-21
.  
In this first-in-human study, SCIB1 ImmunoBody®, incorporating HLA-A*0201 restricted 
epitopes from gp100 and TRP-2 plus HLA-DR*0401 and HLA-DR7/ DR53/DQ6 restricted 
epitopes from gp100 was assessed in HLA- A*0201 melanoma patients with at least one of 
the relevant HLA class-II types. The trial was designed to find the optimal dose of vaccine to 
induce immunological responses and to allow evaluation of safety/tolerability and clinical 
responses. 
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Results  
Patient treatment: 
The trial design is shown in Figure 1 and patient demographics are shown in Table 1. A total 
of 35 patients were recruited, all were evaluated for toxicity and 33/35 for immunological 
responses. Fifteen patients had tumor present at baseline and 20 patients had fully-resected 
disease. The original premise for the study was that patients without a high tumor load might 
respond better to a cancer vaccine; however, first-in-human clinical trials are usually 
restricted to patients with advanced malignant disease.  Although both patients with and 
without tumor present could be recruited into the initial planned dose escalation phase, most 
clinicians enrolled only patients with tumor (Part 1, cohorts 1-3, doses 0.4-4 mg, Figure 1, B). 
In the absence of any obvious toxicity, the highest dose of SCIB1 (4 mg) was selected to dose 
an expanded group of patients with no tumor present (Part 2, cohort 1). During recruitment of 
this cohort advances in the manufacturing methodology enabled us to generate plasmid DNA 
at higher concentrations giving us the potential to administer a higher, 8 mg, dose. A further 
safety cohort of patients receiving 8 mg was therefore added to the dose escalation phase in 
patients with tumor (Part 1, cohort 4) and then an additional cohort, again at 8 mg, was added 
to the expansion phase (Part 2, cohort 2).  Patients with or without tumor present were 
permitted for this final group as an objective tumor response had been observed in a patient 
in the 8 mg safety cohort. 
Dose escalation proceeded without dose limiting toxicity. Twenty-five patients received five 
doses and completed the study; 10 patients withdrew due to progressive disease, two after 
one dose (non-evaluable for immune response), two after three doses and six after four doses. 
In the 2 mg cohort all three patients had their dose escalated to 4 mg after receiving at least 
their first three immunizations (Table 2). Twelve patients received one or more doses of 
SCIB1 in the continuation phase of treatment at approximately 3-monthly intervals, including 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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nine patients with resected disease. No patients received any concurrent melanoma therapy. 
The data presented was collected up to, and including, the point at which all patients had 
completed dosing in the main part of the study. As the hypothesis was that disease-free 
patients would elicit a stronger T cell response than patients with tumor, the data was 
analysed according to whether patients had tumor present or not at study entry and then by 
dose level, rather than by dose alone. 
Immune responses: 
Thirty-three patients were assessed for T cell responses by cultured Elispot and/or 
proliferation assays (Tables 2, 3). The gp100 HLA-A*0201, CD8 epitope is nested within the 
HLA-DR7/DR53/DQ6 epitope so use of the long peptide does not discriminate between CD4 
and CD8 responsesThe responses to the short peptide are likely to be CD8 responses as small 
hydrophobic peptides do not usually bind to HLA- DR7/DR53/DQ6. This is consistent with 
the observation that six patients responded only to the short CD8 peptide. We therefore 
counted these responses separately. Conversely, responses observed with the gp100 
DR7/DR53/DQ6 long peptide could be against the nested HLA-A2-restricted short peptide. 
Indeed, all patients responding to the long peptide also react to the nested short peptide. 
Twenty-six patients were evaluated by Elispot and the results are summarized in Figure 2. 
Six of eight tumor-bearing patients and 17/19 tumor-free patients made a detectable Elispot 
response. Two of the tumor-bearing patients received 4 mg doses; one responded to three 
peptides (Figure 2, A) whereas no responses were seen in samples from the other patient 
(data not shown).  Six tumor-bearing patients received 8 mg doses and strong Elispot 
responses were detected in five patients as exemplified by Figure 2, B-D.  Sixteen tumor-free 
patients received 4 mg doses and 14 of them responded to at least one epitope with 10/14 
responding to all four epitopes (exemplified by Figure 2, E-H). Four tumor-free patients 
received 8 mg doses and three of them responded to at least two epitopes. The intensity of the 
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responses (maximal Elispot count) was significantly higher in patients without tumor in 
patients receiving 4 mg doses compared to those with tumor receiving 4 mg (p< 0.01; Figure 
2, I). In contrast, patients with tumor showed a significantly higher response to the 8mg dose 
than the 4 mg dose (p< 0.03) but there was no significant difference in the patients without 
tumor (Figure 2, I). This suggests that the lower dose of 4 mg was sufficient for the patients 
without tumor but a higher dose is required to overcome the immunosuppression associated 
with bulky tumors. None of the six fully-resected patients receiving the 4 mg dose, who 
continued therapy and eventually received at least 10 doses of SCIB1 responded to all four 
epitopes following the initial five doses; however, all six responded to all four epitopes 
following 10 SCIB1 administrations (Figure 2, J). Overall, of the 26 patients evaluated by 
Elispot, three patients did not respond, three patients responded to one epitope, two patients 
responded to two, two patients responded to three and 16 patients responded to all four 
epitopes. 
Thirty-three patients were evaluated by proliferation and the results are summarized in Figure 
3, Tables 2 and 3. Seven of 13 tumor-bearing patients and all 20 tumor-free patients made a 
detectable proliferation response. A typical proliferation response from a patient to all four 
epitopes is shown in Figure 3, A-D.  Only 1/3 tumor-bearing patients receiving 0.4 mg 
generated a proliferation response, and that was only to a single peptide; 3/3 patients 
receiving 2 mg/4 mg doses, 12/17 patients receiving 4 mg doses and 6/10 patients receiving 8 
mg doses responded to at least two peptides.  Proliferation responses to any peptide were 
observed after three or more doses, but they continued to increase with continued 
administration of SCIB1.  Two of the six fully-resected patients receiving the 4 mg dose, who 
continued therapy and eventually received at least 10 doses of SCIB1, responded with 
proliferative responses to three epitopes following the initial five doses; however, five of six 
had proliferation responses to three or more epitopes following 10 SCIB1 administrations 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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(Figure 3, E). Overall, six patients did not respond, six patients responded to a single epitope, 
six patients responded to two, five patients responded to three and 10 patients responded to 
all four epitopes. 
Patients showed similar responses in both assays used for immune monitoring with 27/33 
(82%) evaluable patients responding in the proliferation assay, 23/26 (89%) in the Elispot 
assay, 21/26 (81%) in both assays and 29/33 (88%) in either assay. 67% (22/33) of patients 
responded to all four epitopes, 85% to TRP2, 76% to gp100A2, 76% to gp100DR4 and 67% 
to gp100DR7/DR53/DQ6 long peptide (shown in graphs as gp100DR7; Tables 2, 3). 100% of 
patients without detectable tumor responded in either assay with 80% responding to all four 
epitopes. In contrast, only 69% of patients with tumor present responded in either assay, with 
46% responding to all four epitopes. 
Correlation of HLA phenotype and T cell responses are shown in Table 3. Only one of the 
patients responding to the gp100 long peptide did not express any of the HLA-
DR7/DR53/DQ6 alleles, but this could indicate a response to the nested CD8 epitope. Ten of 
25 patients responding to the gp100 HLA-DR4 epitope did not express the HLA-DR4 allele 
suggesting that this epitope has a more promiscuous binding and is not just restricted to 
HLA-DR4. Indeed, IEDB (http://tools.iedb.org/mhcii/) predicts that this epitope will bind 
better to HLA-DQ4 than HLA-DR4 ( supplementary Table 1). 
 
Safety assessment:  
The vaccine was well tolerated (Table 4): 218 doses of SCIB1 were administered and there 
were no adverse events (AEs) leading to discontinuation of study treatment. AEs were 
reported as being related to either the study drug, SCIB1, or to the study electroporation 
device/procedure. Overall, 28 patients (80%) had AEs reported related to study drug; there 
was no obvious difference in the rate of AEs in patients with escalating doses or with tumor 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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present at study entry and those with resected disease. The most common of these study drug-
related events (>10%) were injection site hematoma (37%), injection site pain (20%), fatigue 
(14%), blurred vision, headache, and procedural pain (11%). In total, 32 patients (91%) 
experienced AEs related to the electroporation device and procedure, most commonly 
injection site hematoma (77%), injection site pain (37%), procedural pain (17%), and fatigue 
(11%). Grade ≥3 AEs were infrequent and were considered related to SCIB1/EP in only two 
patients (Grade 3 events of injection site hematoma, injection site pain, and anxiety). The 
discomfort associated with the EP device was generally described as tolerable. There were no 
clinically significant changes in laboratory values during the study that were associated with 
SCIB1 administration (data not shown). 
Clinical findings: 
The disease stage, time on study, SCIB1 dosing and disease progression for the 15 patients 
with tumor present at study entry are shown in Figure 4, A and in Table 2. Survival is shown 
in Figure 4, B and in Table 2.  Pre- and post-study treatments are shown in Figure 4, A. Most 
patients had a number of prior lesions that were treated with surgery or decarbazine. No 
patients received checkpoint blockade prior to vaccination as these treatments had not been 
approved at the time of the SCIB1 trial. Four patients received ipilimumab post-vaccination 
and following disease progression. Three of these patients have died and one is still alive.  
One patient with stage IV (M1b) disease with lung metastases at study entry, treated at 8 mg, 
had a RECIST partial response of 29 weeks duration as determined during the main study 
period, per protocol (Figure 4, C). After completing the main study period, new subcutaneous 
lesions identified progression of their disease prior to the patient’s first continuation visit. 
The patient subsequently received vemurafenib and died 19 months after starting study 
participation. A second patient with stage IV (M1b) disease with metastases in the lung, 
lymph nodes, and subcutaneous space, treated at 4 mg, had a greater than 30% reduction in 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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the size of their target lesions but progression of a non-target lesion (Figure 4, D).  The 
patient had a single continuation dose of SCIB1 before a new lesion was detected in the small 
bowel. Following further tumor excision the patient was treated with vemurafenib and died 
31 months after starting the study. Both of these patients had shown strong Elispot and/or 
proliferative responses to all four SCIB1 epitopes. In addition to the patient with a partial 
response, seven patients had a period of stable disease on the study in excess of 16 weeks. 
The disease stage, time on study and SCIB1 dosing for the 20 patients who were disease-free 
at study entry are shown in Figure 4, E and in Table 2. Disease recurrence is shown in Figure 
4, F and in Table 2. Pre- and post-study treatments are shown in Figure 4, E. Most patients 
(17) had multiple lesions that were treated with surgery prior to trial entry. No patients 
received checkpoint blockade prior to vaccination as they had not been approved at the time 
of the trial. One patient received ipilimumab and one received nivolumab post-vaccination 
and both are still alive. The longest follow up is available for the 16 patients treated with 2 
mg and 4 mg of SCIB1; at the cut-off date for reporting, all 16 patients were alive with a 
median observation time of 39 months (range 33 to 52 months). At 2 years, 12 (75%) of these 
patients remained disease-free without additional treatment beyond continued SCIB1.  
Disease-free survival was largely independent of stage at screening with 7/9 (78%) of stage 
III patients and 5/7 (71%) of stage IV patients alive and disease-free at 2 years. All patients 
with resected disease at study entry who received 8 mg doses of SCIB1 (who were recruited 
later than the 4 mg cohort) remained alive and disease-free at the data cut-off point.  
Tumor analysis: 
Following an amendment to the original protocol, pre/post-treatment tumors were obtained 
from 21/35 patients and stained for expression of MHC-I/II, gp100/TRP-2 and PD-L1 plus 
infiltration of CD4, CD8 and Foxp3 positive cells (Table 5). There was great variability in 
expression of these markers between lesions from the same patient. 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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Initially the biopsies taken prior to vaccination were analysed to see if any of the markers 
could predict response to SCIB1. Of interest was the finding that the pre-treatment tumors of 
13 patients showed strong MHC-II expression (>15% of tumor cells expressing MHC-II) and 
this group of patients with MHC-II positive tumors included seven patients who remained 
alive and tumor-free post-resection and post-SCIB1 treatment plus both of the patients with 
CT scan findings of tumor regression.  Of  the eight patients whose pre-treatment tumors did 
not express high levels of MHC-II, only four were disease-free at the end of the main study 
period. Pre-treatment tumor samples from eight patients showed a loss of MHC-I (defined as 
≤80% of tumor cells showing MHC-I expression in any pre-treatment biopsy sample). Five 
of these patients had disease recurrence and one had recurrence and then died (patient 04-28). 
In contrast, of the 13 patients whose tumors did not lose expression of  MHC-I, only four 
were not disease-free (including patient 04-16 who also had evidence of tumor reduction). 
Fifteen patients expressed MHC-I (>80% of tumor cells), MHC-II (>15% of tumor cells) or 
both and only three of these patients had died/recurred or failed to show a reduction in tumor 
burden in response to the vaccine. Six patients had tumors that had lost expression of MHC-I 
(≤80% of tumor cells) and had no elevated expression of MHC-II (>15% of tumor cells). 
Only one of these patients remains disease free. Clinical benefit was superior in MHC-I/II 
positive patients (Fishers exact test p=0.027). 
All pre-treatment tumors tested showed some loss of TRP-2 expression (between 10-100% of 
cells showing no expression) and 14 showed some loss (10-100%) of gp100 expression.  
Expression of PD-L1, infiltration of CD4, CD8 and Foxp3 positive cells or CD4:Foxp3 or 
CD8:Foxp3 ratios did not predict disease recurrence or progression.  
Tumors were obtained post-vaccination from six patients, three who had tumor present and 
three who were fully-resected at study entry. Tumors from one of the fully-resected patients 
(05-09) failed to express either target prior to vaccination and the patient did not benefit from 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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the vaccine as they experienced tumor recurrence. One patient’s recurrent tumor (04-16) had 
a reduction in expression of gp100 and TRP-2. One patient’s post-vaccination tumor (01-19) 
showed a loss of MHC-I and TRP-2. Two patients’ recurrent tumors excluded CD4 T cells 
(04-03 and 04-28) and one patient’s pre- and post-vaccination tumors showed no obvious 
changes (01-37). 
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Discussion  
We conducted a first-in-human phase I/II trial to test the safety and efficacy of a gp100/TRP-
2 antibody DNA vaccine, SCIB1, in melanoma patients. SCIB1 was safe and well tolerated. 
Use of the EP device to administer SCIB1 caused transient pain and, on occasion, injection 
site hematoma but was successfully given on 218 occasions, including administration to five 
patients who have now each received 15-17 immunizations over a period of up to 39 months. 
Discomfort from the EP procedure only limited treatment to three doses in a single patient.  
The SCIB1 vaccine was developed to stimulate T cell responses to both MHC-I and MHC-II 
restricted epitopes from two different melanoma antigens. Eighty-eight percent of patients 
responded to one or more epitopes and 67% of patients responded to all four epitopes, with 
similar responses to both antigens. There were significantly stronger responses to the 8 mg 
dose than to the 2/4 mg doses, indicating that the former is the most appropriate dose for 
future studies. The immune response rate compares favourably with other vaccines targeting 
gp100 (80% v 49%, 
22, 23
) but is a similar response rate to a DNA fusion vaccine targeting 
carcinoembryonic antigen (CEA,
24
), although these comparisons are complicated by different 
assays being used to quantify the immune response in each study. 
Also in line with the CEA study, we show that both the T cell Elispot responses were 
stronger in patients without tumor present at screening than in patients with detectable tumor, 
which suggests that tumor load may attenuate the response. It also suggests that previous 
vaccine studies in patients with tumor load may have underestimated the measurable effects 
due to systemic or local immune suppression. SCIB1 monotherapy may therefore be 
particularly effective in early stage patients with a low tumor burden. At present, interferon-
α2a and ipilimumab are licensed for the adjuvant treatment of melanoma 25, 26.  Ipilimumab 
significantly improved median recurrence-free survival (RFS) from 17.1 to 26.1 months and 
the 3-year RFS of resected high-risk stage III patients from 35% to 47% when compared to 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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placebo, but 52% of patients discontinued treatment due to toxicity 
25
.  Further follow-up has 
shown that this improvement in RFS led to a significant improvement in overall survival 
27
. 
In the current study, all 20 of the fully-resected patients were alive at data cut-off with a 
median observation time of 37 months (range 6 - 52 months) from study entry; the median 
RFS has not been reached and there was minimal toxicity. The 2- and 3-year RFS for the 
stage III patients was 67% and 56%, respectively, and was 71% at both 2 and 3 years for the 
stage IV patients.   
To prevent recurrence of melanoma it would be ideal to stimulate memory responses. In 
animal models, SCIB1 stimulated memory T cell responses that continued to increase in 
avidity as the T cells were selectively recruited into memory 
19
. Similarly, in this current 
study, patients have shown stronger and broader responses following extended treatment with 
SCIB1. All patients on continuation responded to all four epitopes after five continuation 
doses at 21 months or after 10 immunizations; this suggests that vaccination for the 
prevention of recurrence should continue for at least 2 years post-surgery and that 
maintenance vaccination should be considered as it appears to improve the strength and 
breadth of the T cell response to vaccine-encoded epitopes. The former maybe related to 
memory but this is difficult to assess as we did not phenotype these responses. The latter may 
indicate de novo stimulation of new populations of T cells.  
Thirty-eight percent of the tumors biopsied had reduced expression of MHC-I prior to 
vaccination, although none had total loss. One of six patients’ tumors that were resected post-
vaccination showed MHC-I loss (≤80% of cells expressing MHC-I) that was not apparent 
prior to treatment. Tumors lacking MHC-I expression can resist T cell attack and become the 
dominant cell type. Total loss of MHC-I is rare as it makes cells susceptible to attack by 
natural killer (NK) cells, but when it occurs it is usually due to loss or mutation of 
β2microglobulin 
28, 29
. Loss of the specific allele recognized by the T cells is more frequent as 
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this makes the tumor cells resistant to both T cell and NK attack. Unfortunately, allele 
specific monoclonal antibodies do not work in immunohistochemistry analyses on paraffin 
embedded tissue and therefore allele loss could not be assessed.  
Most tumors do not express MHC-II; however, 62% of the tumors in this study showed 
strong MHC-II expression prior to vaccination. MHC-II expression on melanomas has 
previously been described as an indicator of poor prognosis 
30-32
.  However, in this study 9/13 
of the patients whose tumors expressed MHC-II are either disease-free or their tumors 
regressed after SCIB1 treatment. This suggests that MHC-II expression could be a predictive 
biomarker of patients who are likely to respond to immunization. A recent study has shown 
that MHC-II positivity on tumors cells predicted response to anti-PD-1/PD-L1 therapy 
33
. It 
also provides support for the growing evidence that tumor-specific CD4 T cells play a vital 
role in anti-tumor immunity 
34-37
. 
Some of the cells within all of the patients’ pre-treatment tumors showed a loss of TRP-2 
(with 10-100% of cells showing no expression) although, with the exception of one patient, 
expression did not decrease further on post-treatment, recurrent tumors. This suggests that 
there is a either a pre-existing T cell response to TRP-2 in patients which drives selection of 
antigen loss variants or it is lost due to genetic mutation or epigenetic dysregulation. The loss 
of TRP-2 prior to vaccination did not predict outcome; however, this could be explained by 
the expression of gp100 which is also a target for the vaccine and emphasizes the need for 
including more than one antigen in the vaccine design.  Targeting these two antigens may 
also benefit from combination with other drugs which alleviate tumor immune suppression or 
epigenetic control. Indeed, preclinical studies have shown that in combination with 
checkpoint blockade, SCIB1 and SCIB2 (an ImmunoBody® targeting NY-ESO-1), induce 
increased infiltration and proliferation of T cells that result in significantly improved survival 
21, 39
.  In this trial, no patients received checkpoint inhibitors prior to vaccination but six 
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patients (four with tumor and two with no tumor at study entry) received ipilimumab or 
nivolumab post-vaccination and three of these patients are still alive. Although these patient 
numbers are low, this suggests that SCIB1 vaccination may prime for responses to 
checkpoint inhibition. 
In conclusion, SCIB1 is a novel class of anti-cancer immunotherapy that induces T cells 
which can cause tumor regression in patients with melanoma.  The high frequency of 
responses, their breadth and durability suggest SCIB1 is worthy of further study in a larger 
cohort of patients. This is particularly the case in the adjuvant setting, where all of the 
patients responded immunologically and where absence of toxicity is an important clinical 
consideration. Furthermore, the stimulation of potent de novo immune responses by SCIB1 
may provide an opportunity for synergistic combination therapy with checkpoint inhibitors in 
late stage disease.  
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Materials and Methods 
Study design and treatment plan: 
This study is an open label, phase I/II dose escalation study in melanoma patients. The trial 
was designed to find the optimal dose of vaccine to induce immunological responses and to 
allow evaluation of safety/tolerability and clinical responses. Patients with stage III/IV 
melanoma (with or without tumor present at study entry (Part1)) were accrued in sequential 
cohorts to receive 0.4, 2 or 4 mg of SCIB1 via intramuscular injection with EP. Patients with 
fully-resected stage III/IV disease (Part 2) were treated at the maximum tolerated dose 
(MTD; or the highest dose administered in Part 1 if no MTD was determined). SCIB1 was 
administered at two injection sites every 3 weeks for three doses and then twice more at 12 
and 24 weeks. Dose escalation was only permitted following a safety evaluation by the 
Cohort Review Committee of a minimum of three patients in each cohort followed up to the 
week 7 visit.  Dose-limiting toxicities (DLTs) were defined as either Grade 3/4 neutropenia 
with fever and/or infection or any non-hematological toxicity or autoimmunity/allergy equal 
to or greater than Grade 3 (CTCAE, version 4.02). Patients receiving the 2 mg dose were 
permitted to escalate to the 4 mg dose in the absence of DLTs after their first three doses.  
Patients without any intercurrent toxicity by week 28 were permitted to continue treatment 
every 12-24 weeks for up to 5 years. All patients were followed up for a minimum of 2 years 
after study end or until death.  The UK Gene Therapy Advisory Committee provided ethical 
approval for the study, which was conducted in accordance with the Declaration of Helsinki 
and with Good Clinical Practice as defined by the International Conference on 
Harmonization. As no MTD had been reached at 4 mg in the initial Part 1 dose escalation 
phase, a fourth cohort of five patients with tumors present was recruited and dosed with 8 mg 
SCIB1 (Part 1, cohort 4) in parallel with the recruitment of resected patients into the first Part 
2 cohort. This was possible due to improvements in the manufacturing process for the DNA, 
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which enabled a higher concentration of plasmid DNA solution to be prepared which, with 
the volume restrictions for intramuscular injection, enabled an 8 mg dose to be administered. 
Once safety at this higher dose had been demonstrated, an additional group of patients was 
then recruited into a second Part 2 cohort to receive 8 mg doses (either with or without tumor 
present at study entry).   
Although, adjuvant interferon-α2a was a treatment option for fully-resected patients, the 
physicians involved in this trial did not routinely use it as standard of care.  Ipilimumab was 
not licensed for adjuvant use when the patients were dosed.  Ipilimumab and pembrolizumab 
became available for use as standard of care at a later date and, indeed, some of the patients 
received these treatments if they had progressive disease or a recurrence. The patients 
receiving SCIB1 therefore received no concurrent therapy for their melanoma. 
Eligibility criteria: 
Patients were eligible for enrolment if they had histologically confirmed stage III or IV 
melanoma. Part 1 comprised of patients with either resected disease or patients with 
advanced disease who had measurable disease evaluable by the Response Evaluation Criteria 
in Solid Tumors (RECIST version 1.0). In Part 2, recruitment was limited to patients with 
resected disease (4 mg cohort) or patients with or without tumor present at screening (8 mg 
cohort). In both parts, patients with fully resected disease could not receive systemic therapy 
between resection and study registration. All patients needed to be positive for HLA-A2 and 
at least one of HLA-DR4, HLA-DR7, HLA-DR53 or HLA-DQ6. Other inclusion criteria 
included an Eastern Cooperative Oncology Group performance status of ≤2 and adequate 
liver function and lymphocyte counts. Exclusion criteria included the presence of brain 
metastases, a life-expectancy of less than 3 months, any prior systemic anti-cancer treatment 
or immunosuppressive therapy within 4 weeks of study entry, previous malignancy within 5 
years of screening, the presence of any electronic stimulation device, cardiac abnormalities 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
 
 
 20 
and women who were pregnant or lactating. All patients provided written informed consent 
prior to enrolment. 
Evaluations at baseline and during treatment: 
Screening procedures and assessments consisted of a complete medical history, a full clinical 
examination, baseline electrocardiogram, ophthalmologic examination, assessment of vital 
signs, HLA tissue typing, pregnancy test (if appropriate) and standard biochemical, 
hematological and urine analysis. Tumor status at screening was determined by a CT scan of 
the head, thorax, pelvis and abdomen. 
The safety and tolerability of SCIB1 and the EP device were monitored throughout by 
clinical examination, assessment of the injection site, evaluation of vital signs and laboratory 
parameters, recording of AEs and a patient tolerability questionnaire.  Patients with tumor at 
screening were further assessed at weeks 9, 18 and 28 along with a CT scan prior to any 
additional SCIB1 dose given during continuation treatment. Patients were followed up in 
clinic for a minimum of 2 years with CT scans where appropriate for suspected disease 
progression. 
Stimulation of naïve and memory immune responses and the response to multiple injections 
were assessed by standard proliferation and interferon-gamma (IFNγ) Elispot assays at 
baseline and before and after subsequent immunizations. Detailed methodology for these 
assays (in compliance with MIATA guidelines) and immunohistochemistry is reported in 
supplementary data. For the proliferation assays, a patient was designated as an 
immunological responder if on two or more time points post-dosing the proliferation index 
(PI) was double the pre-treatment PI; the PI was defined as the mean peptide-specific counts 
per minute (cpm) divided by the mean negative control cpm at a given time point.  For the 
Elispot assays, a patient was designated as an immune responder if on two occasions or more 
post-dosing the mean peptide-specific Elispot response minus two Standard Deviations was 
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greater than the mean pre-treatment peptide-specific response plus one Standard Deviation 
(of this mean) and the peptide-specific Elispot response was more than 50 spots per million 
peripheral blood mononuclear cells (PBMCs). 
Clinical study statistics 
The primary endpoint for Part 1 of the study was the safety and tolerability of SCIB1 
administered by electroporation. No sample size was determined for this part as it was 
designed to seek an MTD that could not be predicted in advance. The sample size for Part 2 
(4 mg dose) of the study was based on Fleming's single stage procedure 
40, 41
. The highest 
immune response probability given the null hypothesis of no drug effect was set at 50% and 
the lowest immune response probability of the alternative hypothesis was set at 75%. This 
requires the study of at least 13 patients for a two-sided significance of 0.05 and 80% power.  
The sample size for the expansion of Part 2 (8 mg dose) was also based on Fleming’s single 
stage procedure. As three patients (up to six) were to be enrolled in the Part 1 4 mg cohort, an 
additional 10 patients were planned to provide a total of 13 patients receiving the same dose. 
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Figure Legends 
Figure 1. Patient recruitment and analysis. (A) Participant flowchart.  Patients were initially 
recruited sequentially into Part 1, cohorts 1, 2 and 3.  Resected patients were then recruited 
into Part 2 cohort 1 at a dose of 4 mg.  A further cohort of patients was recruited in parallel 
with Part 2 cohort 1 at a higher dose of 8 mg (Part 1 cohort 4) and then Part 2 was expanded 
to dose patients at this 8 mg dose (Part 2 cohort 2). (B) Patient data was analysed based on 
whether tumor was present or not at screening and then by dose level. *One patient in each of 
Part 1 cohort 1 and cohort 3 only received a single injection and were replaced. **Intra-
patient dose escalation to 4 mg permitted. 
Figure 2.  Generation of IFNγ (A-H) in response to immunization with SCIB1. PBMC were 
isolated at the indicated study visits and cultured for 10 - 17 days at 37
o
C with HLA-A2-
restricted TRP-2 peptide or with HLA-A2-restricted, HLA-DR4-restricted or HLA-
DR7/DR53/DQ6-restricted gp100 peptides. IFNγ was assayed on days 10 and 17 by Elispot 
following a 24 hour re-stimulation with the appropriate peptide. Data is shown from one 
timepoint for each patient. Representative Elispot data is shown for patient 04-16 (day 10), a 
patient with tumor present at screening and receiving 4 mg doses of SCIB1 (A); three patients 
with tumor present at screening and receiving 8 mg doses of SCIB1 (01-46 (day 10), 04-27 
(day 17) and 04-28 (day 17) in panels B, C and D, respectively); and four fully-resected 
patients receiving 4 mg doses of SCIB1 (05-09 (day 10), 05-11 (day 10), 05-18 (day 17) and 
05-21 (day 10) in panels E, F, G and H, respectively). The results shown are the mean 
number of IFNγ producing cells ± standard deviation (n=4). Study visit days in the main 
study are denoted by the prefix “D” and in the continuation phase by “C” where Cx0y 
indicates x=weeks after dosing and y=continuation dose number. (I) Maximum mean of four 
wells IFNγ spot count for individual antigens determined for each responder. Non-parametric 
statistics (Mann Whitney test) were used for comparison of the results between cohorts. 
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Antigen response defines the number of responses to any one epitope by any patient against 
the number of potential responses for the number of patients tested. (J) Administration of >10 
doses of SCIB1 conveys a broader range of epitope recognition in fully-resected 4 mg 
patients compared to five administrations. The bar represents the median antigen recognition; 
the P value was calculated by the Mann Witney test). Individual colours represent individual 
patients i.e. 05-11 (black), 05-24 (red), 01-32 (blue), 05-19 (yellow), 05-21 (green) and 05-18 
(purple). 
 
Figure 3.  T cell proliferation in response to immunization with SCIB1.  PBMCs were 
isolated from patient 05-13 (tumor not present at screening; 4 mg dose) at the indicated study 
visits (days) and cultured for up to 11 days at 37
o
C following stimulation with (A) TRP-2 
(HLA-A2-restricted) peptide; (B) gp100 (HLA-A2-restricted) peptide; (C) gp100 (HLA-
DR4-restricted) peptide; or (D) gp100 (HLA-DR7/DR53/DQ6-restricted) peptide. On days 7 
and 11 cellular proliferation was assayed by the overnight incorporation of 
3
H-thymidine.  
The results shown are the mean of the calculated Proliferation Index (PI) ± standard error of 
the mean (n=3). (E) Administration of >10 doses of SCIB1 conveys a broader range of 
epitope recognition in fully-resected 4 mg patients compared to five administrations. The bar 
represents the median antigen recognition; the P value was calculated by the Mann Witney 
test). Individual colours represent individual patients i.e. 05-11 (black), 05-24 (red), 01-32 
(blue), 05-19 (yellow), 05-21 (green) and 05-18 (purple).  
 
Figure 4.  Clinical findings and tumor regression in patients immunized with SCIB1.  (A) 
Swimmer plot for patients with tumor present at study entry (n=15). Information about other 
treatments given post-SCIB1 was collected in follow-up; dates, duration and response data 
were not collected. (B) Kaplan-Meier analysis of the overall survival of patients who had 
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tumor at study entry and received at least three doses (2-8 mg) of SCIB1 (n=10). (C) CT 
scans of lung lesions of patient 04-28 before and 6 months after treatment with SCIB1. 
Lesion locations are indicated by arrows. (D) CT scans of lung lesions of patient 04-16 
before and 9 months after treatment with SCIB1. (E) Swimmer plot for patients with fully-
resected tumor at study entry (n=20). (F) Kaplan-Meier analysis of the recurrence-free 
survival of patients with fully-resected tumor at study entry (n=20).  
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TABLES 
Table 1. Patient Demographics 
Characteristic 
Tumor present 
at baseline 
Tumor not present 
at baseline 
Overall 
n % n % n % 
Number 15  20  35  
Age       
 Range 36-75  25-74  25-75  
 Median 64  60  60  
Sex       
 Male 7 46.7 11 55.0 18 51.4 
 Female 8 53.3 9 45.0 17 48.6 
Stage at study entry
1
       
 III 1
2
 6.7 12 60.0 13 37.1 
 IV 14 93.3 8 40.0 22 62.8 
  M1a 2 14.3 5 62.5 7 31.8 
  M1b 6 42.9 2 25.0 8 36.4 
  M1c 6 42.9 1 12.5 7 31.8 
Primary site       
 Head 3 20.0 2
3
 9.5 5 14.3 
 Neck 1 6.7 1 4.8 2 5.7 
 Upper extremity 
 Lower extremity 
 Trunk 
 Mucosal 
 Other 
 Unknown 
0 
3 
4 
1 
3 
0 
0 
20.0 
26.7 
6.7 
20.0 
0 
2 
7 
6 
0 
2 
1 
9.5 
33.3 
28.6 
0 
9.5 
4.8 
2 
10 
10 
1 
5 
1 
5.7 
28.6 
28.6 
2.9 
14.3 
2.9 
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History       
 Superficial spreading 6 40.0 11 52.4 17 48.6 
 Nodular 4 26.7 6 28.6 10 28.6 
 Lentigo maligna 2 13.3 0 0 2 5.7 
 Acral lentiginous 0 0 1 4.8 1 2.9 
 Other 3 30.0 2 9.5 5 14.3 
Lactose dehydrogenase (LDH) at study entry
4
      
 ≥ 450 IU/L 3 20.0 3 15.0 6 17.1 
 < 450 IU/L 12 80.0 17 85.0 29 82.9 
1 Tumor status prior to excision is shown for patients with resected disease at study entry. 
2 One patient had non-measurable lesions present and was stage III (M0). 
3 One patient had two primary sites recorded: head and other (right axillary fold). 
4 Values at week 0, apart from two patients where samples were not tested; screening values used. 
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Table 2. Clinical Findings and Immune Responses  
Patient 
no. 
No. of 
doses 
Stage at 
study 
entry or 
prior to 
resection 
Months 
from 
resection 
to study 
entry 
Months to 
progressive 
disease1/ 
recurrence2 
Time to 
death 
(months) 
Status 
(months 
since first 
dose) 
Immune responses to HLA-restricted 
epitopes 
No. of 
peptides 
recognized TRP-2 
A2 
gp100 
A2 
gp100 
DR4 
gp100 
DR7 
/DR53 
/DQ6 
TUMOR PRESENT AT STUDY ENTRY 
DOSE = 0.4 mg 
01-01* 4 IV (M1c) NA 2 7 Dead   P  1 
02-01* 4 IV (M1b) NA 4 16 Dead     0 
02-04* 3 IV (M1c) NA 2 7 Dead     0 
03-06 1 IV (M1c) NA 1 2 Dead NE NE NE NE  
DOSE = 2 mg/4 mg 
01-16* 3 + 2 IIIB (M0) NA 2 14 Dead P P P P 4 
01-19* 4 + 1 IV (M1a) NA 6 - Alive 
(55) 
P P   2 
DOSE = 4 mg 
03-13 1 IV (M1c) NA <1 1 Dead NE NE NE NE  
04-16 5 + 2c IV (M1b) NA 4 31 Dead P E P E P P E 4 
05-05 4 IV (M1c) NA 4 13 Dead     0 
DOSE = 8 mg 
01-46 5 IV (M1c) NA 4 - Alive 
(25) 
E E E E 4 
01-49 4 IV (M1a) NA 4 5 Dead E E E E 4 
04-27 5 + 1c IV (M1b) NA 9 - Alive 
(28) 
P E E E E 4 
04-28 5 + 1c IV (M1b) NA 8 19 Dead P E P E E Pc E 4 
05-26 3 IV (M1b) NA 1 12 Dead     0 
05-27 4 IV (M1b) NA 5 17 Dead P E  P E  2 
TUMOR NOT PRESENT AT STUDY ENTRY 
DOSE = 2 mg/4 mg 
01-24* 3 + 2 IV (M1a) 6 - - Alive 
(52) 
P P   2 
DOSE = 4 mg 
01-32 5 + 5c IIIC 4 33 - Alive 
(39) 
Ec E Pc E P E 4 
01-34 5 IIIC 5 - - Alive 
(41) 
P E P P P 4 
01-37 5 IV (M1a) 6 14 - Alive P E E P E E 4 
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
 
 
 28 
(40) 
02-21 5 IIIB 4 - - Alive 
(39) 
P E E E E 4 
02-33 5 IIIB 5 - - Alive 
(35) 
P E   2 
04-03* 5 IV (M1a) 1 17 - Alive 
(49) 
P    1 
04-22 3 x 
2mg 
IV (M1b) 4 - - Alive 
(37) 
P P P E 4 
05-08 5 + 3c IIIC 5 15 - Alive 
(41) 
P E P E E Pc E 4 
05-09 5 IIIA 2 4 - Alive 
(41) 
P E E E E 4 
05-11 5 + 9c IV (M1a) 2 - - Alive 
(36) 
Pc Ec Pc E P E P E 4 
05-13 5 IIIC 11 - - Alive 
(40) 
P P E P E P E 4 
05-18 5 + 9c IV (M1a) 4 - - Alive 
(33) 
Ec P Ec P Ec P Ec 4 
05-19 5 + 8c IIIA 5 - - Alive 
(36) 
Pc Ec P Ec P E P Ec 4 
05-21 5 + 11c IV (M1c) 5 - - Alive 
(36) 
P Ec Pc Ec Pc Ec Pc E 4 
05-24 5 + 9c IIIA 2 - - Alive 
(36) 
Pc Ec Pc E Pc E Pc E 4 
DOSE = 8 mg 
01-51 5 + 2c IV (M1b) 5 - - Alive 
(13) 
P E P E P E P E 4 
01-54 5+1c IIIC 4 - - Alive (9) E P E P E P E 4 
04-43 5 IIIC 3 - - Alive (6) P P P P 4 
06-03 5 IIIC 3 - - Alive (6) P E  P E  2 
Proliferation responders   23 17 18 15  
Elispot responders   20 19 19 19  
Responders in either assay  28 25 25 22  
Abbreviations: HLA, human leukocyte antigen; P, proliferation; E, Elispot; NE, non-evaluable; NA, 
not applicable; c, continued administration of SCIB1. 
*
Only screened in proliferation assay. 
1
Time to disease progression according to RECIST is given for patients with tumor present at study 
entry (patient 01-16 had non-measurable lesions at study entry and time to clinical progression is 
given); 
2
Time to recurrence is given for patients with fully-resected tumors at study entry. 
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Table 3.  HLA Typing and Immune Responses 
 
Patient no. Peptide response DR7/DR53/DQ6 
TRP-2 
A2 
gp100 
A2 
gp100 
DR4 
gp100 DR7 
/DR53 
/DQ6 
DR7 DR53 DQ6 
TUMOR PRESENT AT STUDY ENTRY 
DOSE 
DOSE = 0.4 mg 
 
01-01   P     
02-01        
02-04        
03-06 NE NE NE NE    
DOSE = 2 mg/4 mg 
 
 
01-16 P P P P    
01-19 P P      
DOSE = 4 mg 
 
03-13 NE NE NE NE    
04-16 P E P E P P E    
05-05        
DOSE = 8 mg 
 
 
01-46 E E E E    
01-49 E E E E    
04-27 P E E E E    
04-28 P E P E E Pc E    
05-26       ND 
05-27 P E  P E     
TUMOR NOT PRESENT AT STUDY ENTRY 
DOSE 
DOSE = 2 mg/4 mg 
 
 
01-24 P P      
DOSE = 4 mg 
 
01-32 Ec E Pc E P E    
01-34 P E P P P    
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01-37 P E E P E E    
02-21 P E E E E    
02-33 P E      
04-03 P       
04-22 P P P E    
05-08 P E P E E Pc E    
05-09 P E E E E    
05-11 Pc Ec Pc E P E P E    
05-13 P P E P E P E    
05-18 Ec P Ec P Ec P Ec    
05-19 Pc Ec P Ec P E P Ec    
05-21 P Ec Pc Ec Pc Ec Pc E    
05-24 Pc Ec Pc E Pc E Pc E    
DOSE = 8 mg 
 
01-51 P E P E P E P E    
01-54 E P E P E P E    
04-43 P P P P    
06-03 P E  P E     
Abbreviations: HLA, human leukocyte antigen; P, proliferation; E, Elispot; NE, non-
evaluable; ND, not done; c, continued administration of SCIB1.  
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Table 4. Common Adverse Events and Relatedness to SCIB1 and Electroporation Procedure 
 All Tumor Present Tumor Not Present 
≥G1 ≥G1 
Drug-
related 
≥G1 
EP-
related 
≥G3 ≥G1 ≥G1 
Drug-
related 
≥G1 
EP-
related 
≥G3 ≥G1 ≥G1 
Drug-
related 
≥G1 
EP-
related 
≥G3 
n (%) of patients 
35 (100) 15 (43) 20 (57) 
General disorders & 
administration site 
conditions 
- Injection site 
hematoma 
- Injection site pain 
- Fatigue 
32 (91) 
 
 
27 (77) 
 
13 (37) 
9 (26) 
20 (57) 
 
 
13 (37) 
 
7 (20) 
5 (14) 
31 (89) 
 
 
27 (77) 
 
13 (37) 
4 (11) 
3 (9) 
 
 
1 (3) 
 
1 (3) 
0 
14 (40) 
 
 
9 (26) 
 
4 (11) 
5 (14) 
5 (14) 
 
 
1 (3) 
 
0 
4 (11) 
13 (37) 
 
 
9 (26) 
 
4 (11) 
2 (6) 
1 (3) 
 
 
0 
 
0 
0 
18 (51) 
 
 
18 (51) 
 
9 (26) 
4 (11) 
15 (43) 
 
 
12 (34) 
 
7 (20) 
1 (3) 
18 (51) 
 
 
18 (51) 
 
9 (26) 
2 (6) 
2 (6) 
 
 
1 (3) 
 
1 (3) 
0 
Musculoskeletal & 
connective tissue 
disorders 
- Arthralgia 
- Pain in extremity 
- Back pain 
- Musculoskeletal pain 
17 (49) 
 
 
5 (14) 
5 (14) 
3 (9) 
3 (9) 
10 (29) 
 
 
3 (9) 
3 (9) 
1 (3) 
1 (3) 
9 (26) 
 
 
1 (3) 
3 (9) 
0 
1 (3) 
0 
 
 
0 
0 
0 
0 
6 (17) 
 
 
2 (6) 
1 (3) 
2 (6) 
1 (3) 
3 (9) 
 
 
1 (3) 
0 
1 (3) 
1 (3) 
3 (9) 
 
 
1 (3) 
0 
0 
1 (3) 
0 
 
 
0 
0 
0 
0 
11 (31) 
 
 
3 (9) 
4 (11) 
1 (3) 
2 (6) 
7 (20) 
 
 
2 (6) 
3 (9) 
0 
0 
6 (17) 
 
 
0 
3 (9) 
0 
0 
0 
 
 
0 
0 
0 
0 
Gastrointestinal 
disorders 
- Constipation 
- Nausea 
13 (37) 
 
5 (14) 
4 (11) 
5 (14) 
 
1 (3) 
2 (6) 
2 (6) 
 
1 (3) 
1 (3) 
1 (3) 
 
0 
0 
9 (26) 
 
3 (9) 
4 (11) 
4 (11) 
 
1 (3) 
2 (6) 
1 (3) 
 
1 (3) 
1 (3) 
1 (3) 
 
0 
0 
4 (11) 
 
2 (6) 
0 
1 (3) 
 
0 
0 
1 (3) 
 
0 
0 
0 
 
0 
0 
Infections & 
infestations 
- Nasopharyngitis 
- Rhinitis 
13 (37) 
 
3 (9) 
3 (9) 
3 (9) 
 
1 (3) 
0 
1 (3) 
 
0 
0 
1 (3) 
 
0 
0 
4 (11) 
 
1 (3) 
0 
1 (3) 
 
0 
0 
0 
 
0 
0 
1 (3) 
 
0 
0 
9 (26) 
 
2 (6) 
3 (9) 
2 (6) 
 
1 (3) 
0 
1 (3) 
 
0 
0 
0 
 
0 
0 
Injury, poisoning & 
procedural 
complications 
- Procedural pain 
- Post-procedural 
hematoma 
12 (34) 
 
 
6 (17) 
3 (9) 
7 (20) 
 
 
4 (11) 
3 (9) 
9 (26) 
 
 
6 (17) 
3 (9) 
0 
 
 
0 
0 
3 (9) 
 
 
2 (6) 
0 
1 (3) 
 
 
1 (3) 
0 
3 (9) 
 
 
2 (6) 
0 
0 
 
 
0 
0 
9 (26) 
 
 
4 (11) 
3 (9) 
6 (17) 
 
 
3 (9) 
3 (9) 
6 (17) 
 
 
4 (11) 
3 (9) 
0 
 
 
0 
0 
Nervous system 
disorders 
- Headache 
- Dizziness 
11 (31) 
 
7 (20) 
4 (11) 
5 (14) 
 
4 (11) 
2 (6) 
4 (11) 
 
2 (6) 
2 (6) 
0 
 
0 
0 
8 (23) 
 
5 (14) 
4 (11) 
4 (11) 
 
3 (9) 
2 (6) 
4 (11) 
 
2 (6) 
1 (3) 
0 
 
0 
0 
3 (9) 
 
2 (6) 
0 
1 (3) 
 
1 (3) 
0 
0 
 
0 
0 
0 
 
0 
0 
Respiratory, thoracic & 
mediastinal disorders 
- Dyspnea 
- Cough 
- Oropharyngeal pain 
11 (31) 
 
 
4 (11) 
3 (9) 
3 (9) 
1 (3) 
 
 
1 (3) 
0 
0 
1 (3) 
 
 
1 (3) 
0 
0 
1 (3) 
 
 
1 (3) 
0 
0 
5 (14) 
 
 
4 (11) 
2 (6) 
0 
1 (3) 
 
 
1 (3) 
0 
0 
1 (3) 
 
 
1 (3) 
0 
0 
1 (3) 
 
 
1 (3) 
0 
0 
6 (17) 
 
 
0 
1 (3) 
3 (9) 
0 
 
 
0 
0 
0 
0 
 
 
0 
0 
0 
1 (3) 
 
 
0 
0 
0 
Skin & subcutaneous 
tissue disorders 
- Rash 
11 (31) 
 
4 (11) 
4 (11) 
 
2 (6) 
1 (3) 
 
1 (3) 
0 
 
0 
4 (11) 
 
1 (3) 
1 (3) 
 
0 
0 
 
0 
0 
 
0 
7 (20) 
 
3 (9) 
3 (9) 
 
2 (6) 
1 (3) 
 
1 (3) 
0 
 
0 
Psychiatric disorders 
- Depressed mood 
- Anxiety 
10 (29) 
4 (11) 
3 (9) 
2 (6) 
0 
1 (3) 
1 (3) 
0 
1 (3) 
2 (6) 
0 
1 (3) 
6 (17) 
2 (6) 
1 (3) 
1 (3) 
0 
0 
0 
0 
0 
1 (3) 
0 
0 
4 (11) 
2 (6) 
2 (6) 
1 (3) 
0 
1 (3) 
1 (3) 
0 
1 (3) 
1 (3) 
0 
1 (3) 
Eye disorders 
- Vision blurred 
7 (20) 
5 (14) 
4 (11) 
4 (11) 
2 (6) 
2 (6) 
0 
0 
2 (6) 
2 (6) 
2 (6) 
2 (6) 
1 (3) 
1 (3) 
0 
0 
5 (14) 
3 (9) 
2 (6) 
2 (6) 
1 (3) 
1 (3) 
0 
0 
Table shows all adverse events reported for three or more patients (all causality). 
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G = Grade; Drug-related = probably related, possibly related or unlikely to be related to study drug; EP-related = probably 
related, possibly related or unlikely to be related to device or procedure. 
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Table 5.  Percentage Expression of Markers Present on Patient Tumor Biopsies 
 
Patient 
No. 
Pre/ 
Post 
MHC-I 
Tumor 
MHC-II 
Tumor 
gp100 TRP2 FoxP3 
 
CD3 
 
CD4 CD8 PD-L1 
Tumor 
Tissue site 
01-19 Pre 90 1 100 20 10 75 30 60 1 Skin 
Pre 90 2 100 25 20 70 50 60 1 Skin 
Pre 90 2 100 25 15 85 50 40 1 Neck node 
Pre 90 3 100 10 10 90 50 30 3 Skin 
Pre 95 1 100 10 7 80 60 55 1 Neck node 
Pre 95 2 100 70 10 85 10 50 3 Parotid nodule 
Pre 85 3 95 45 10 75 50 30 1 Skin 
Pre 90 1 100 10 10 55 30 30 2 Skin with nodule 
Pre 100 40 90 70 N/A N/A 0 N/A 2 Lymph node 
Post 70 30 100 10 5 60 40 N/A 3 Lymph node 
01-24 Pre 90 1 100 100 0 0 0 0 1 Skin 
Pre 95 2 40 10 5 60 10 50 3 Lymph node 
Pre 95 10 0 0 5 50 1 45 2 Lymph node 
Pre 100 1 4 20 5 N/A 20 65 2 Skin 
01-32 Pre 90 1 100 10 1 75 40 50 2 Skin 
Pre 80 1 100 33 5 N/A 60 55 2 Skin 
Pre 90 1 100 10 5 65 60 65 1 Skin 
01-34 Pre 85 4 50 10 7 90 60 55 2 Skin 
Pre 90 10 100 10 5 90 10 30 2 Lymph tissue 
01-37 Pre N/A N/A N/A 70 N/A N/A N/A N/A 4 Lymph node 
Pre 70 15 90 0 N/A 90 80 60 1 IIiac artery node 
Pre 90 4 100 0 7 85 70 65 1 Skin 
Pre 90 2 N/A N/A 0 N/A 0 N/A 1 Skin 
Pre 80 3 100 0 10 75 45 60 2 Skin 
Pre 90 5 100 0 10 85 50 70 2 Skin 
Pre 85 1 100 0 15 70 30 55 2 Skin 
Post 95 1 100 1 40 80 70 75 2 Skin 
Post 95 3 100 0 15 90 50 65 N/A Skin 
01-46 Pre 90 5 100 0 5 95 80 15 20 Lymph node 
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Pre 20 8 100 10 3 60 40 10 2 Left Lung 
01-49 Pre 90 50 75 10 5 90 70 N/A 8 Right cheek 
Pre 95 70 100 0 20 65 55 25 8 Lymph node  
01-51 Pre 90 30 100 50 5 90 0 30 2 Skin right occiput 
Pre 100 50 100 95 5 60 30 25 1 Skin right ear 
Pre 90 80 50 0 2 50 0 50 2 Skin right ear 
01-54 Pre 90 40 90 33 15 85 70 50 2 Skin 
Pre 80 70 100 100 N/A N/A 50 N/A 1 Skin left flank 
Pre 80 60 33 20 5 90 70 30 2 Skin, left groin 
02-21 Pre 90 1 80 15 10 70 30 40 1 Abdomen 
Pre 90 10 100 0 7 75 30 85 1 Skin 
Pre 90 90 100 15 5 90 50 45 2 Lymph node 
02-33 Pre 80 10 0 0 10 N/A 50 N/A 1 Lymph node 
04-03 Pre 50 1 90 5 10 80 40 65 2 Right neck 
Post 95 50 95 10 5 80 40 35 2 Left breast 
Post 80 10 70 20 7 60 50 70 2 Left chest 
Post 90 30 70 30 10 75 50 90 2 Right breast 
Post 90 10 50 10 2 90 0 20 1 Right upperarm 
04-16 Pre 100 70 100 5 N/A 85 80 50 2 Lower back 
Pre 100 80 95 5 5 0 60 50 2 Lower back 
Pre 90 40 95 1 0 50 20 50 2 Lower back 
Pre 90 80 67 75 5 85 50 N/A 4 Right flank 
Post 70 50 20 25 20 90 60 70 2 Left flank 
Post 90 60 10 10 1 75 30 50 2 Small bowel 
04-27 Pre 85 70 50 5 20 85 80 50 2 Posteria right calf 
Pre 90 10 100 5 20 90 80 50 1 Lateral right calf 
Pre 100 1 100 90 20 90 30 15 1 Right leg 
Pre 90 20 95 20 10 90 20 65 1 Right leg 
Pre 95 10 90 20 10 95 90 40 2 Right ankle 
Pre 100 1 100 5 5 75 0 25 1 Right shin 
Pre 100 1 95 25 5 60 50 30 1 Right shin 
Pre 100 20 95 30 20 60 90 35 1 Right shin 
Pre 90 10 0 0 5 70 50 15 1 Right calf 
Pre 95 2 100 20 15 60 70 10 1 Right ankle 
Pre 80 5 100 5 25 70 80 80 1 Left arm 
04-28 Pre 100 80 100 100 N/A N/A N/A N/A 2 Right upper back 
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Pre 100 80 100 100 N/A 50 50 50 2 Sentinel node local 
Pre 100 40 100 100 N/A 100 50 N/A 1 Right posterior 
shoulder 
Pre 50 40 100 60 N/A 100 10 80 8 Right scapula 
Post 100 50 100 50 N/A 100 30 60 0 Left breast 
Post 100 10 100 10 N/A 100 0 60 2 Right costal margin 
Post 100 10 100 50 N/A 100 0 65 2 Right upper chest 
Post 100 80 100 70 N/A N/A 0 N/A 0 Right shoulder 
05-09 Pre 90 70 0 0 25 70 50 50 1 Left axillary node 
Post 70 15 0 0 5 55 30 35 1 Left axillary node 
Post 50 5 0 0 5 N/A N/A 20 1 Left axillary node 
05-11 Pre 90 15 N/A N/A 10 N/A N/A N/A 2 Axilla lymph node 
05-13 Pre 90 30 N/A N/A 5 N/A N/A N/A 2 Axilla lymph node 
05-18 Pre 100 50 100 50 20 50 N/A 60 2 Left groin 
05-19 Pre 90 50 45 0 15 60 50 30 4 Axilla lymph node 
05-21 Pre 100 50 95 10 5 45 10 85 8 Pancreas 
Patient numbers in black refer to patients who either remained recurrence-free or had evidence of tumor 
reduction post-SCIB1 treatment (patients 04-16 and 04-28).  Patient numbers in red refer to patients who had 
tumor recurrence/progression and/or died. 
Post-tumor samples are shaded in blue. 
Values in bold and blue refer to pre-treatment tumor samples that showed ≤80% MHC-I or >15% MHC-II 
expression. 
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Figure 1  
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Figure 2 
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Figure 3  
Phase I/II clinical trial of SCIB1 in metastatic melanoma. 
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Figure 4 
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Supplementary Information 
 
SCIB1 structure: 
SCIB1 is a plasmid encoding a human IgG1 antibody molecule into which epitopes from 
overexpressed melanoma antigens have been inserted into the CDR as described elsewhere 
9
. 
The HLA-A*0201 epitope from TRP-2180-188 (SVYDFFVWL) was grafted into the CDR H2 
site alongside an HLA-DR4 restricted gp100 44-59 epitope (WNRQLYPEWTEAQRLD) and  
gp100 174-190 epitope restricted by HLA-DR7, HLA-DR53 and HLA-DQ6 
(TGRAMLGTHTMEVTVYH) inserted into both the CDR H3, L1  and CDR H1, L3 sites 
respectively. Nested within gp100 174-190 is also the HLA-A*0201 restricted epitope gp100178-
186 (MLGTHTMEV). The SCIB1 antibody can no longer bind to antigen. Both the heavy and 
light chain antibody sequences are within separate expression cassettes both under control of 
a CMV immediate-early promoter terminating with a BGH polyadenylation signal in the 
FDA regulatory compliant plasmid backbone of pVax1 (Invitrogen, UK) for use in humans. 
Clinical grade DNA was manufactured according to Good Manufacturing Practice guidelines 
at Cobra Biologics (Keele, UK), formulated at either 2 mg/ml or 4 mg/ml in phosphate-
buffered saline and stored frozen at -20°C. After thawing, the vaccine was administered using 
a TriGrid
TM
 Delivery System EP device provided by Ichor Medical Systems, Inc. (San Diego, 
USA) according to the manufacturer’s instructions.   
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Immunological analysis: 
 
All immunological studies were conducted in a laboratory that operates under exploratory 
research principles. Standard operating procedures were used in all laboratory studies. 
Demographics of donors are given in Table 1. Responders and non-responders are shown in 
Table 2, according to the pre-set definitions of “immunological responder” in the 
proliferation assay and Elispot assays (defined below). Raw data and SOPs are available from 
Scancell Ltd through the corresponding author but these may be subject to non-disclosure 
agreements. 
 
PBMC isolation: Peripheral blood samples (approx. 60ml) were drawn into lithium heparin 
tubes (Becton Dickinson, cat no 367526). Samples were transported at room temperature and 
processed within 8 hours of venepuncture (median time to processing 5 hours 7 mins, range 
15 mins - 8 hours). PBMCs were isolated from each sample by density gradient 
centrifugation using Ficoll-Hypaque (Sigma, cat no 10771). Proliferation and cultured Elispot 
assay of PBMCs were performed immediately after PBMC isolation. The median number of 
PBMCs routinely derived from patient samples was 4.9 x10
7
, range 1.6x10
7
-20x10
7
. The 
mean viability as assessed by trypan blue exclusion was 93%, range 90-95%.  
 
PBMC stimulation: Peptides (>98% purity) used for the immunological analyses were 
supplied by GenScript Inc. and stored lyophilized at -80°C.  These included two HLA-A2-
restricted peptides, TRP-2180-188 (SVYDFFVWL) and gp100178-186 (MLGTHTMEV), an 
HLA-DR4 restricted gp10044-59 peptide (WNRQLYPEWTEAQRLD) and a gp100174-190 
peptide restricted by HLA-DR7, HLA-DR53 and HLA-DQ6 (TGRAMLGTHTMEVTVYH).  
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On the day of use the peptides were reconstituted to a final concentration of 1mg/ml in 10% 
(v/v) dimethyl formamide (Sigma, cat no 227056) in deionized sterile distilled water (Gibco, 
cat no 10977).  
 
Proliferation assays: PBMCs (1.5×10
6
 cells/well) were stimulated with individual peptides at 
a final concentration of 10μg/ml in 2.0ml of complete media (RPMI supplemented with l-
glutamine (Sigma cat no G7513) and penicillin/streptomycin Sigma, cat no P4333, final 
concentration of 0.1mg/ml streptomycin and 100 units/ml penicillin) and 10 %(v/v) 
autologous plasma). Stimulation with purified protein derivative (Statens Serum Institute, cat 
no 2390, final concentration 20µg/ml) and CEF, a mixture of peptides from cytomegalovirus, 
Epstein Barr and influenza viruses (Mabtech, cat no 3615-1, final concentration of 4 µg/ml), 
served as positive controls.  As a negative control, PBMC were incubated with peptide 
vehicle alone.  PBMC were cultured at 37°C in 5% CO2 and proliferative capacity assessed at 
4-5, 7 and 11-12 days post-stimulation by overnight 
3
H-thymidine incorporation (Perkin 
Elmer, cat no NET027Z005MC).   
The PI was defined as the mean peptide-specific counts per minute (cpm) divided by the 
mean negative control cpm at a given time point.  A patient was designated as an 
immunological responder in the proliferation assay if on two or more time points post-dosing 
the PI was double the pre-treatment PI.  
 
Human interferon-gamma (IFN) Elispot assay:  
Freshly isolated PBMC (3×10
6
 cells/well in 24-well flat-bottomed plates), were stimulated 
with individual peptides at a final concentration of 10μg/ml in 4.0ml of complete media 
supplemented with human recombinant IL-7 (Peprotech, cat no 200-07, final concentration 
20ng/ml) and IL-15 (Peprotech 200-15, final concentration 10ng/ml).  PBMC stimulated by 
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vehicle alone served as a negative control.  PBMC were cultured at 37°C in an atmosphere of 
5% CO2 and supplemented with 10 IU/ml human recombinant interleukin-2 (Pepotech, cat no 
200-02) after 3 days. After 14 days culture 1.0ml of spent media was removed from wells and 
replaced with fresh media supplemented as described with IL7, IL-15 and IL-2. Cytokine 
release by stimulated T cells was assessed after 10 days and 17 days in IFNγ Elispot assays 
using capture and detection reagents according to the manufacturer’s instructions (Mabtech, 
cat no 3420-2A). In brief, an anti-IFNγ antibody was coated onto the wells of a 96-well 
Immobilin-P plate Millipore, cat no MSIPS4510).  Cultured PBMCs were used at 5 x 10
4 
cells/well (in quadruplicate) and stimulated with the relevant peptides at 10µg/ml (200µL 
final volume). Addition of vehicle or phytohaemagglutinin (Sigma, cat no L1668, final 
concentration 10µg/ml) served as negative and positive controls respectively, respectively.  
After 20 hours incubation at 37°C in an atmosphere of 5% CO2, captured IFNγ was detected 
by the addition of a biotinylated anti-IFNγ antibody and spots were identified with a 
streptavidin alkaline phosphatase and chromogenic substrate (BioRad, cat no 170-6432).  
Spots were analyzed and counted using an automated plate reader (Cellular Technologies 
Ltd.) using Immunospot version 3.2 software. Analysis was performed using “autocount easy 
blue” with an optical sensitivity of 240, background 10, diffuse spot process 20 and min-max 
spot range of 0.002-8.77mm. A representative Elispot scan is given in supplementary Figure 
1. 
A patient was designated as an immune responder in the Elispot assay if on two occasions or 
more post-dosing the mean peptide-specific Elispot response minus two Standard Deviations 
was greater than the mean pre-treatment peptide-specific response plus one Standard 
Deviation (of this mean) and the peptide-specific Elispot response was more than 50 spots 
per million PBMC.  
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Immunohistochemistry and Evaluation  
All tumor samples received were incised, fixed in formaldehyde and embedded in paraffin 
wax. For immunohistochemistry, 4µm thick sections from each tumor sample were cut onto 
X-tra slides (Leica). Briefly tissue slides were dewaxed with xylene and rehydrated through 
three changes of graded alcohol. Antigen retrieval (except for PD-L1) was achieved by 
immersing sections in sodium citrate buffer (1M, pH6) and heating for 20 minutes in an 
800W microwave. For PD-L1, sections were immersed three times in EDTA (1mM, pH9) 
and microwaved for 5 minutes. All slides were then cooled in water. 
Endogenous peroxidase activity was blocked using Peroxidase Block for 5 minutes 
(Novolink). Slides were washed with Tris-Buffered Saline (TBS, pH6.0) followed by 
addition of 100µl Protein Block for 5 minutes (Novolink). After another wash with TBS, 
primary antibody optimally diluted in Leica antibody diluent (as described in supplementary 
Table 1) was applied to sections and incubated for 60 minutes. Slides were washed with TBS 
followed by incubation with 100µl Post Primary Blocking solution (Novolink) for 30 
minutes. After washing in TBS, sections were incubated with 100µl Novolink polymer for 30 
minutes. Sections were washed in TBS. Visualization was achieved using 3, 3′-
diaminobenzidine tetra hydrochloride (DAB, Novolink), and then lightly counterstained with 
haematoxylin (Novolink), dehydrated in alcohol, cleared in xylene (Genta Medica), and 
mounted with distyrene, plasticizer and xylene (BDH Chemicals). 
Cores were imaged using a NanoZoomer (Hamamatsu). Immunostaining was evaluated by a 
histopathologist blinded to the clinical trial. Assessment of staining was based on a semi-
quantitative approach using the percentage of cells stained subjectively estimated to produce 
a final score in the range 0-100%. 
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Supplementary Tables: 
Supplementary Table 1:  Source and dilution of antibodies used in immunohistochemistry 
of patient biopsies. 
 
 
 
  
Antibody Clone Isotype Dilution Source Cat.number 
MHC-I EMR8-5 
Class I 
Mouse IgG1 1/5000 Abcam Ab70328 
MHC-II CR3/43 Mouse IgG1, 
kappa 
1/200 Dako M0775 
CD3 F7.2.38 Mouse IgG, kappa 1/60 Dako A0452 
gp100 EP4863(2) Rabbit IgG 1/100 Abcam Ab137078 
TRP2 - Rabbit polyclonal 
IgG 
1/1000 Abcam Ab74073 
FoxP3 236A/E7 Mouse IgG1 1/100 Abcam Ab20034 
CD4 4B12 Mouse IgG1,kappa 1/50 Dako M7310 
CD8 C8/144B Mouse monoclonal 1/50 Dako M7103 
PD-L1 
(CD274) 
E1L3N Rabbit monoclonal 
IgG 
1/50 Cell 
Signaling 
13684 
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Supplementary Figure 1: 
A representative 11-day cultured IFNγ Elispot of patient 05-11-D309. This patient showed a 
response to the HLA-DR4 restricted gp10044-59 peptide (WNRQLYPEWTEAQRLD). 
Cells were cultured for 11 days in media (columns 2, 3), TRP2 (columns 4, 5) gp100A2 
(columns 6, 7), gp100DR4 (columns 8, 9) and gp100DR7 (columns 10, 11) before an 
overnight re-stimulation with media (rows A, B), PHA (rows G, H). D2, D3 and E2, D3 
served as additional media control wells. Wells D4, D5 and E4, E5 were re-stimulated with 
TRP2, D6, D7 and E6, E7 with gp100A2, D8, D9 and E8, E9 with gp100DR4 and D10, D11 
and E10, E11 with gp100DR7. 
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Supplementary: Table 1. Top ten IEDB predictions for binding of the HLA-DRB1*04:01 epitope (WNRQLYPEWTEAQRL)  to 
MHC-II alleles  
 
  Allele Start End Peptide Method used Percentile 
rank 
HLA-DQA1*03:03/DQB1*04:01(DQ4) 1 15 WNRQLYPEWTEAQRL NetMHCIIpan 12.39 
HLA-DRB1*04:01 1 15 WNRQLYPEWTEAQRL Consensus 
(smm/nn/sturniolo) 
13.12 
HLA-DQA1*03:01/DQB1*03:02 2 16 NRQLYPEWTEAQRLD Consensus 
(comb.lib./smm/nn) 
16.05 
HLA-DRB1*08:01 1 15 WNRQLYPEWTEAQRL sturniolo 18.52 
HLA-DRB1*13:01 1 15 WNRQLYPEWTEAQRL sturniolo 19.92 
HLA-DQA1*05:01/DQB1*02:01(DQ5) 1 15 WNRQLYPEWTEAQRL Consensus 
(comb.lib./smm/nn) 
19.29 
HLA-DQA1*01:01/DQB1*05:01 1 15 WNRQLYPEWTEAQRL Consensus 
(comb.lib./smm/nn) 
26.14 
HLA-DRB1*03:01 2 16 NRQLYPEWTEAQRLD Consensus 
(smm/nn/sturniolo) 
27.98 
HLA-
DPA1*01:03/DPB1*04:01(DP0401) 
1 15 WNRQLYPEWTEAQRL NetMHCIIpan 32.74 
HLA-DPA1*01:03/DPB1*04:02 1 15 WNRQLYPEWTEAQRL NetMHCIIpan 34.08 
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